Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
伊布替尼和硼替佐米联合治疗后进行伊布替尼维持治疗，用于治疗复发或难治性套细胞淋巴瘤和高危特征：欧洲 MCL 网络的 1/2 期试验 (SAKK 36/13)
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.102221
Novak, Urban; Fehr, Martin; Schär, Sämi; Dreyling, Martin; Schmidt, Christian; Derenzini, Enrico; Zander, Thilo; Hess, Georg; Mey, Ulrich; Ferrero, Simone; Mach, Nicolas; Boccomini, Carola; Böttcher, Sebastian; Voegeli, Michèle; Cairoli, Anne; Ivanova, Vanesa-Sindi; Menter, Thomas; Dirnhofer, Stefan; Scheibe, Bernhard; Gadient, Sandra; Eckhardt, Katrin; Zucca, Emanuele; Driessen, Christoph; Renner, Christoph
